2024 Annual Results Forecast

SZSIJan 18 00:00 · Announcements

Rendu Bio (688193.SH): It is expected to have a net loss of 6.7 million to 10 million yuan in 2024.

Gelonghui, January 17: RenDu Biology (688193.SH) announced that 1. According to preliminary calculations by the finance department, the company expects to achieve a net income attributable to the parent company's owners of -6.7 million yuan to -10 million yuan in 2024, which represents a decrease of 14.96 million yuan to 18.26 million yuan compared to the same period last year (statutory disclosure data), a year-on-year decrease of 181% to 221%. 2. It is expected that the net income attributable to the parent company's owners, excluding non-recurring gains and losses, will be -18.05 million yuan to -21.35 million yuan in 2024, which is compared to the same period last year (statutory disclosure data).

Gelonghui FinanceJan 17 17:38

Express News | The largest increase in margin balance this week: TaxFriend's margin balance: 0.028 billion yuan, balance increase: 222.96%; Rendo Biotechnology's margin balance: 0.04 billion yuan, balance increase: 142.4%

BreakingsNov 3, 2024 20:20

Third Quarter Report 2024

SZSIOct 30, 2024 00:00 · Announcements

RenDu Biology (688193.SH) plans to distribute 1 yuan for every 10 shares at the interim dividends, with ex-rights and ex-dividends on October 30th.

Announcement from Rendo Biotech (688193.SH), the company plans to distribute a cash dividend of 1 per 10 shares for the first half of 2024...

Zhitong FinanceOct 21, 2024 16:37

2024 Semi-Annual Report

SZSIAug 30, 2024 00:00 · Announcements